NAT was administered to 33 (53.2%) HER2+/HR-negative patients, to 46 (27.9%) HER2+/HR+ patients, to 66 (7.1%) HER2-negative/HR-positive patients and to 30 (30.3%) triple negative breast cancer patients. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.